American Moderna Estimated The Rate Of Vaccination From Covid-19 At $25-30
The American biotech company Moderna is negotiating to sell its developed coronavirus vaccine for $25-30 per dose, that is, the course of its vaccinations will cost $50-60, the Financial Time newspaper reports, citing sources familiar with the negotiations with potential buyers.
This price is provided for the United States and other high-income countries, but, as the publication notes, it is unlikely to be final, since the cost discussed with Moderna was significantly higher than that offered by other developers of COVID-19 vaccines.
So, the American Pfizer and its German partner BioNTtech are going to sell 100 million doses of the vaccine to the US for $19.5, and the British-Swedish AstraZeneca signed a deal to sell a dose of the future vaccine for $3-4 to France, Italy, Germany, and the Netherlands.
Moderna, Pfizer, and Merck have previously stated that they intend to profit from the sale of their vaccines, while AstraZeneca and Johnson & Johnson do not intend to profit from this, at least in the early stages of the pandemic.
Moderna earlier this week began large-scale trials of its anti-coronavirus vaccine on 30,000 volunteers - the largest trials in the world.